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Currently, 25 states and Washington DC have enacted full medical marijuana (MMJ)
programs while 18 states allow limited access to MMJ products. Limited access
states permit low (or zero) tetrahydrocannabinol (THC) and high cannabidiol (CBD)
products to treat specified conditions such as uncontrolled epilepsy. Although MMJ
products are derived from the same plant species as recreational MJ, they are often
selected for their unique cannabinoid constituents and ratios, not typically sought by
recreational users, which may impact neurocognitive outcomes. To date, few studies
have investigated the potential impact of MMJ use on cognitive performance, despite a
well-documented association between recreational marijuana (MJ) use and executive
dysfunction. The current study assessed the impact of 3 months of MMJ treatment
on executive function, exploring whether MMJ patients would experience improvement
in cognitive functioning, perhaps related to primary symptom alleviation. As part of a
larger longitudinal study, 24 patients certified for MMJ use completed baseline executive
function assessments and 11 of these so far have returned for their first follow-up
visit 3 months after initiating treatment. Results suggest that in general, MMJ patients
experienced some improvement on measures of executive functioning, including the
Stroop Color Word Test and Trail Making Test, mostly reflected as increased speed in
completing tasks without a loss of accuracy. On self-report questionnaires, patients also
indicated moderate improvements in clinical state, including reduced sleep disturbance,
decreased symptoms of depression, attenuated impulsivity, and positive changes in
some aspects of quality of life. Additionally, patients reported a notable decrease in their
use of conventional pharmaceutical agents from baseline, with opiate use declining more
than 42%.While intriguing, these findings are preliminary and warrant further investigation
at additional time points and in larger sample sizes. Given the likelihood of increasedMMJ
use across the country, it is imperative to determine the potential impact of short- and
long-term treatment on cognitive performance as well as the efficacy of MMJ treatment
itself.
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INTRODUCTION
Over the last several decades, although marijuana (MJ) users in
the US have historically sought out MJ for recreational purposes,
a growing number are exploringMJ for medical purposes. In fact,
it is estimated that over 1.2millionmedicalMJ (MMJ) consumers
are currently registered in the US (Procon.org1). According to
Procon.org, although the majority of states have mandatoryMMJ
registration (CO, MA) other states have voluntary registration
(e.g., CA, ME) or do not require registration (WA). While the
number of current US MMJ consumers is only an estimate, it
is likely that the number of certified patients will continue to
grow as the public becomes increasingly aware of and open
to the potential therapeutic effects of MMJ. Legal marijuana
is considered the fastest growing market in the United States,
with a current estimated value of $6.7 billion, which could
reach 21.8 billion by 2020 (ArcView Market Research, 2016). In
1996, California became the first state to fully legalize MMJ and
since then, another 24 states, and the District of Columbia have
followed suit with full legalization for medical purposes, while an
additional 18 states have limited MMJ laws, allowing only the use
of products containing a specific non-psychoactive cannabinoid
(cannabidiol [CBD]). Four states and the District of Columbia
have also approved recreational MJ use, with several additional
states pending legislation. Recent national surveys (Center for
Behavioral Health Statistics and Quality, 2015; Johnston et al.,
2015) report that MJ is retaining its status as the most widely
used illicit drug for recreational purposes in the world; nearly
22.2 million Americans report use within the past month (Center
for Behavioral Health Statistics and Quality, 2015). Further, while
more than a million Americans are registered MMJ patients, this
estimate does not include the unknown number of consumers
currently taking hemp-derived products, marketed as high CBD-
containing compounds (tinctures, oils, topicals), which are
widely available from a number of vendors who do not require
MMJ certification. Despite the rapid changes in policy, many
legislators, consumers, physicians, and the general public remain
misinformed about MJ. Although used for centuries as medicine
by varied cultures across the world, in the US, MMJ became part
of mainstream medicine in 1850, when it was added to the US
Pharmacopeia. Physicians prescribed the use of MJ broadly for a
range of indications including (but not limited to) pain, emesis,
migraine, insomnia, epilepsy, and opium withdrawal (Birch,
1889; Potter, 1917; Grinspoon and Bakalar, 1997; Booth, 2003)
and it remained widely available until 1937, when the marijuana
tax law criminalized use of the substance. As anti-MJ sentiments
grew across the country, it was removed from the pharmacopeia
in 1942 and in 1970, the passage of the Controlled Substances Act
(CSA) declared MJ a Schedule I substance and the cultivation,
possession, and distribution of MJ became prohibited. According
to the Drug Enforcement Administration (DEA), Schedule I
drugs are those “with no currently accepted medical use, no
demonstrated safety profile and a high potential for abuse...[they]
1Medical Marijuana ProCon.org. (2016). Retrieved June 16, 2016, from http://
medicalmarijuana.procon.org/
Procon org (2016). Number of Legal Medical Marijuana Patients. Retrieved from
http://medicalmarijuana.procon.org. March 3).
are the most dangerous drugs of all the drug schedules
with potentially severe psychological or physical dependence”
(dea.gov2; Comprehensive Drug Abuse Prevention and Control
Act of 19703). This classification deems MJ more dangerous
than other substances including cocaine, methamphetamine,
and opiate-based drugs, which ironically are responsible for
approximately 30,000 deaths per year (Centers for Disease
Control and Prevention, 2015). In fact, opioid overdoses are
now considered a national epidemic; the rate of opioid overdose
deaths, including those related to both prescription pain relievers
and heroin, has nearly quadrupled since 1999 (Centers for
Disease Control and Prevention, 2015). Given its Schedule I
classification, research studies exploring both potential risks and
benefits of MMJ have faced numerous obstacles, forcing policy
to outpace science in recent years. As the national climate warms
towardMJ, research is slowly pushing forward. However, much is
left to be explored before the gap between science and policy can
begin to close.
A growing body of evidence suggests that recreational MJ
use adversely impacts the brain, particularly during critical
periods of neurodevelopment, including adolescence (For review:
Crean et al., 2011; Jacobus and Tapert, 2014; Lisdahl et al.,
2014). Numerous studies have shown that MJ users, particularly
those who initiate use during adolescence, exhibit deficits across
multiple cognitive domains. For example, MJ users who initiate
use during adolescence exhibit deficits in attention (Ehrenreich
et al., 1999; Cousijn et al., 2013; Becker et al., 2014) and
processing speed (Fried et al., 2005; Medina et al., 2007; Lisdahl
and Price, 2012; Jacobus et al., 2015). Furthermore, lower scores
on measures of IQ (Pope et al., 2003; Meier et al., 2012; Crane
et al., 2015) have been observed among adolescent MJ users,
although recent work has questioned this finding (Jackson et al.,
2016; Mokrysz et al., 2016), and a number of studies have
reported poorer verbal memory among adolescent and adult MJ
smokers (Tait et al., 2011; Auer et al., 2016; Shuster et al., 2016).
Data also suggest that adolescent MJ use is strongly associated
with poorer executive functioning (Fontes et al., 2011; Solowij
et al., 2012; Crane et al., 2013; Dougherty et al., 2013; Tamm et al.,
2013; Becker et al., 2014; Hanson et al., 2014; Winward et al.,
2014; Jacobus et al., 2015; Sagar et al., 2015) even when deficits
in other domains are not observed (Gruber et al., 2012a).
In contrast, although research is in its infancy, given what
is currently known about MJ, it is possible that MMJ use may
not lead to the same neurocognitive consequences that have
been observed in recreational users. Although recreational
and medical MJ are derived from the same plant species,
there are inherent differences that exist between the two. As
recreational users most frequently seek a mood altering, often
“euphoric” or “mellow” state, they primarily utilize products
with considerable amounts of THC, the main psychoactive
ingredient in MJ (Wachtel et al., 2002; Zeiger et al., 2010). Over
the last two decades the potency of recreational marijuana has
significantly increased from approximately 4 to 12% between
1995 and 2014 in response to consumer demand (ElSohly et al.,
2Retrieved June 16, 2016, Available online at: http://www.dea.gov/index.shtml
3Comprehensive Drug Abuse Prevention and Control Act of 1970, Pub. L. No.
91-513, 84 Stat. 1236, 21 U.S.C. §812.
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2016). In contrast, MMJ users primarily initiate MMJ use as a
means of symptom alleviation (Nunberg et al., 2013), and as
such are likely to seek products for their therapeutic potential
rather than to experience the psychoactive effects. They may
therefore use products differently and purchase products with a
markedly different chemical composition from more common
recreational products. These MMJ products are often (but not
always) high in other cannabinoids, such as cannabidiol (CBD)
which has been touted for its therapeutic potential, and which
is not psychoactive. CBD has become best known in recent
years for its potential to treat those with intractable seizure
disorders, specifically children with Dravet Syndrome or Lennox
Gastaux Syndrome, and preliminary data from both anecdotal
reports and recent clinical trials are promising. In a recent
open-label trial in patients aged 1–30 with severe, intractable,
childhood-onset, treatment-resistant epilepsy, Devinsky et al.
(2016) reported that the median monthly frequency of motor
seizures decreased from 30 per month at baseline to 15.8
per month during the treatment period in patients treated
with Epidolex, a 98% purified CBD compound created by
GW Pharma. CBD has also demonstrated promise in treating
other conditions including chronic pain, multiple sclerosis
(Giacoppo et al., 2015), and Huntington’s disease (Consroe et al.,
1991) as well as psychiatric and behavioral health conditions
including anxiety (for review: Blessing et al., 2015) and psychosis
(Zuardi et al., 2009; Leweke et al., 2012). Interestingly, some
work suggests that CBD may have a pharmacological profile
similar to that of antipsychotic medications (Zuardi et al.,
2012). In addition to CBD, a host of other cannabinoids,
many of which are non-psychoactive, are also often present
in MMJ products, and becoming increasingly popular. Other
phytocannabinoids, including cannabigerol (CBG), cannabinol
(CBN), cannabichromene (CBC), tetrahydrocannabinolic
acid (THCA), and tetrahydrocannabidivarin (THCV), have
shown therapeutic potential and may also reduce some of
the undesirable effects associated with THC. For example,
cannabichromene (CBC), another abundant cannabinoid, has
anti-inflammatory effects (Izzo et al., 2012) and has recently
been shown to increase the viability of adult neural stem
progenitor cells (NSPCs), essential for brain plasticity and
suggestive of neurogenesis (Shinjyo and Di Marzo, 2013).
In addition, cannabigerol (CBG) inhibits GABA uptake, has
anti-inflammatory properties, and has also been touted as being
neurogenic (Borelli et al., 2013; Valdeolivas et al., 2015), while
tetrahydrocannabidivarin (THCV) has been shown to inhibit
some of the negative cognitive and physiologic effects of THC
and may be neuroprotective (Englund et al., 2016).
Despite the majority of states with MMJ laws and more
than a million registered patients, no studies to date have
utilized a pre- vs. post-design model to examine the specific
impact of MMJ on cognitive performance as a primary outcome
variable. As noted above, cognitive deficits are demonstrated in
chronic, heavy, recreational MJ users who begin MJ use during
adolescence (for review: Crean et al., 2011; Jacobus and Tapert,
2014; Lisdahl et al., 2014), and while some clinical trials of MMJ
(particularly CBD) have been initiated in children for treatment-
resistant epilepsy (Devinsky et al., 2016), the majority of those
utilizing MMJ products are adults, and beyond the most critical
period of neurodevelopmental vulnerability. In addition, it is
likely that if physical or psychological symptoms are addressed
by MMJ use, cognitive function may improve. For example,
studies have reported that anxiety often interferes with both
attention and executive function (e.g., Vytal et al., 2013); if
MMJ products act as an anxiolytic for at least some patients as
reported, this may result in better concentration and enhanced
cognitive performance. Chronic pain has also been noted to
impair cognitive performance, notably tasks requiring attentional
and executive function (for review see Moriarty et al., 2011).
Accordingly, if patients experience a reduction in pain-related
symptoms as a result of MMJ treatment, it is likely that cognitive
performance will improve relative to a pre-treatment assessment.
In order to evaluate the impact of MMJ use on cognitive
function and determine the efficacy of MMJ in a broad sample
of MMJ patients, we designed a longitudinal study which assesses
MMJ patients at baseline and after 3, 6, and 12 months of
MMJ treatment. Importantly, baseline measurements were taken
prior to the initiation of MMJ treatment in order to obtain an
“MJ naïve” assessment. Given the differences between MMJ and
recreational MJ use and the reported potential for symptom
alleviation in MMJ users, we hypothesized that MMJ patients
would demonstrate improved cognitive performance on tasks
of executive functioning, as well as improved clinical state and
quality of life following MMJ treatment. This study is currently
ongoing, and in this paper, we report our preliminary cognitive
findings in addition to information regarding general health and
clinical state measures as well as medication use, after 3 months
of MMJ treatment.
MATERIALS AND METHODS
Participants
To date, 32 participants completed screening procedures, of
which 24 MMJ users were successfully enrolled in the current
study. Data from 11 patients’ baseline and 3-month check-in
visits (Visit 2) were available for preliminary analysis. In order
to qualify for study entry, participants are required to either
be MJ naïve or if they have a history of MJ use, they must
report MJ abstinence for 10 or more years in an effort to ensure
that recent MJ exposure does not impact results. Self-report
MJ status was confirmed with urinalysis. Participants are also
required to have a valid certification for MMJ, and may report
seeking MMJ treatment for a variety of indications; the current
sample (n = 11) reported MMJ certification for anxiety (n = 5),
depression (n= 3), chronic pain (n= 7), sleep (n= 5), and other
conditions (n= 6). Notably, 9 of 11 participants reported seeking
out MMJ treatment for two or more conditions or symptoms.
Study Design
Prior to participation, study procedures were thoroughly
explained, and all participants were required to read and sign an
informed consent form. This document describes the procedures,
risks, benefits, and voluntary nature of the study. All study
procedures were approved by the Partners Institutional Review
Board (IRB).
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Prior to initiating MMJ treatment, all enrolled participants
completed a neurocognitive battery as well as measures of clinical
state, quality of life, sleep, and general health assessments. In
addition, eligible patients completed neuroimaging sessions (i.e.,
functional and structural magnetic resonance imaging), which
will be reported in subsequent publications. Following 3 months
of regular MMJ treatment, participants returned for a check-
in visit (Visit 2) and repeated all study measures. In addition,
once patients began a regular MMJ use regimen, they were
contacted by phone to complete monthly check-in visits, which
assessed type, frequency and magnitude of MMJ use using a
modified timeline follow-back procedure (TLFB; Sobell et al.,
1998) and other queries. During check-in calls, patients were
asked to provide qualitative information regarding product type
and strain of MMJ products used as well as mode of use
(i.e., joint, vaporizer, tincture, edibles, etc.) and quantitative
information regarding frequency (episodes of MMJ use/week)
and magnitude (doses/week) of use. These data were reviewed,
clarified, and corroborated in person during Visit 2. Each
participant also provided a sample of his/her most frequently
used MMJ product, which was analyzed by an outside laboratory
(ProVerde Laboratories, Inc.) in order to obtain cannabinoid
constituent profiling for each product, providing information on
THC and CBD levels as well as a number of other cannabinoids.
These data will be examined in future investigations in order
to determine the impact of constituent ratios on cognitive and
clinical outcomes.
Cognitive and Clinical Assessments
All subjects completed the Wechsler Abbreviated Scale of
Intelligence (WASI; Wechsler, 1999), which provides an estimate
of overall cognitive functioning, to ensure an estimated IQ of
75 or higher. As a part of a larger neurocognitive battery, each
individual completed several measures of executive functioning,
including the Stroop Color Word Test, the Trail Making Test,
the Wisconsin Card Sorting Test (WCST), and Letter-Number
Sequencing subtest of the Wechsler Adult Intelligence Scale
(WAIS). The Stroop Color Word Test (MacLeod, 1991) assesses
the ability to inhibit an automatic, overlearned response. While
the first condition of the task (Color Naming) assesses rapid
naming abilities, the second condition (Word Reading) requires
that the individual read words printed in black ink which also
serves as a primer for the third task (Interference) where they
must inhibit the natural tendency to read the words aloud and
instead must name the color of the ink words are printed in.
During the Interference condition, each word is printed in a
color incongruous to the actual word (i.e., red printed in green,
or blue printed in red). The Trail Making Test (Lezak et al.,
2004) is comprised of two timed conditions where participants
must connect a series of dots. Trails A measures psychomotor
function, visual scanning, and attention by asking participants
to connected dots in numerical order. Trails B incorporates
alternating set demands, requiring participants to alternate
between numbers and letters (e.g., 1, A, 2, B, etc.), in order
to measure cognitive flexibility and executive function. The
WCST (Berg, 1948; Lezak et al., 2004) is a robust measure of
executive functioning, which also assesses cognitive flexibility
and set-shifting. All participants completed a computerized
administration of the task in which they must match cards based
on sorting rules and adjust to changing sorting rules based
solely on feedback as to whether each match is either correct
or incorrect. Finally, during the Letter-Number Sequencing
task (Wechsler, 1997), participants are read increasingly longer
strings of numbers and letters and are asked to repeat them, first
citing the numbers in order, and then the letters in alphabetical
order. Performance on this task is correlated with executive
function and working memory abilities. Subjects completed all
tasks at baseline and at the 3-month follow-up visit, with the
exception of the WASI, which was administered only at baseline
in order to obtain an IQ estimate.
In order to determine whether patients experienced any
change in clinical symptoms or health-related measures which
could potentially impact cognitive performance, each participant
completed a battery of clinical state assessments, including the
Profile of Mood States (POMS), Beck Depression Inventory
(BDI), Beck Anxiety Inventory (BAI), and Barratt Impulsiveness
Scale (BIS) as well as quality of life and general health
questionnaires including the Pittsburgh Sleep Quality Index
(PSQI) and Short-Form 36 Health Survey (SF-36). The POMS
(Pollock et al., 1979) measures self-perceived mood, and
generates subscores for feelings of vigor, confusion, tension,
anger, depression, and fatigue, which combine to generate an
overall measure of Total Mood Disturbance (TMD). The BDI
(Beck et al., 1961) and BAI (Beck and Steer, 1990) are brief
self-report measures that directly assess symptoms of depression
and anxiety. The BIS (Patton et al., 1995) assesses self-reported
impulsivity across three discrete domains (Attention, Motor, and
Non-Planning), which together provide an overall composite
score. The PSQI (Buysse et al., 1989) provides a measure
of sleep quality over the past month. The SF-36 (Ware and
Sherbourne, 1992) questionnaire is a multi-purpose, short-form
health survey that yields an eight-scale profile of functional
health and well-being scores for the following domains: physical
functioning, physical role limitations, emotional role limitations,
energy/fatigue, emotional well-being, social functioning, pain,
and general health.
In addition, patients’ use of conventional pharmaceutical
medications was also tracked in order to determine whether
MMJ use might be related to changes in other medication use.
At baseline and during Visit 2, participants provided a list of
medications used on at least a weekly basis. These medications
were then coded into different classes, including opiates,
antidepressants, mood stabilizers, benzodiazepines, sedatives,
and muscle relaxants. Percent change data based on number of
doses taken per week was calculated for medication use from
baseline to Visit 2.
Statistical Analyses
Descriptive statistics (e.g., mean and standard deviation) were
calculated for demographic and MMJ use variables. Paired t-tests
were used to assess within-subjects changes from baseline to Visit
2. Given our hypotheses that MMJ treatment would be associated
with improved cognitive performance, clinical state, and general
health ratings, one-tailed t-tests were utilized throughout.
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RESULTS
Demographics
As reported in Table 1, participants (6 males, 5 females) enrolled
in current study were between the ages of 32 and 74, with an
average age of 48.91. Generally, participants were well-educated,
having all earned at least a high school diploma, and were of at
least average intelligence, as noted on the WASI. All reported
using MMJ at least weekly since the initiation of regular MMJ
treatment (1–7 days per week; 4.95 days on average). Half of the
sample reported typical use of MMJ products more than once per
day; patients reported MMJ use 1.78 times per day on average,
resulting in an average weekly total of 9.30 episodes per week.
With regard to product type and mode of use, the majority of
participants (8 of 11) reported using flower products in some
form (smoked or vaporized). Reported use of concentrates and
oils (3 of 11) and “medibles” (MMJ edible products; 3 of 11) by
participants was less frequent. Other modes of administration
(i.e., topicals) were not reported among the current sample.
Cognitive Performance
As shown in Table 2, following 3 months of MMJ treatment,
participants completed Trails A significantly faster (p = 0.02)
and also tended to complete Trails B (p = 0.06) faster relative
to baseline. Further, this improvement was not at the expense of
task accuracy, as no difference in number of errors was observed
across visits for Trails A or Trails B. On the Stroop Color
Word Test, participants also demonstrated faster completion
times and some improvements in task accuracy following 3
months of treatment. As compared to baseline, performance on
the Color Naming condition was significantly faster (p = 0.01),
TABLE 1 | Demographics and MMJ use.
Demographic variable (n = 11) Mean (SD)
Age 48.91 (15.13)
Education (years) 15.82 (1.47)
WASI full scale IQa 117.09 (7.49)
MMJ useb
Days of MMJ use/week 4.95 (2.26)
Times/day used 1.78 (1.19)
Total MMJ use episodes/week 9.30 (8.86)
Mode of usec Number of participants
Smoke (flower product) 5
Vaporize (flower product) 6
Vaporize (oil/concentrates) 2
Oil/concentrates (non-smoked/vaporized) 1
Tincture 3
Mediblesd 3
aWASI, Wechsler Abbreviated Scale of Intelligence.
bMMJ use reflects average use from the start of regular treatment through Visit.
cBased on 11 participants’ reported mode(s) of use.
dMedibles, MMJ edible products.
again with no decrement noted in percent accuracy. Performance
was virtually unchanged across visits on the Word Reading
subtest, which is primarily utilized to prime participants for
the Interference condition. During the Interference condition,
participants also demonstrated faster completion times relative to
baseline (p = 0.01). Although no improvement was detected for
accuracy on the Interference condition, participants maintained
their high levels of performance from baseline to their 3-month
check in visits. Overall on the WCST, no changes in performance
were observed for categories completed, correct responses or
perseverative errors, and although some improvements were
noted from baseline to Visit 2, these did not reach statistical
significance. On the Letter Number Sequencing task, while the
total number correct increased slightly from baseline to Visit 2,
this difference did not reach statistical significance.
Clinical Ratings and Pharmaceutical
Medication Usage
As noted in Table 3, several discrete measures of clinical state
and general health improved relative to baseline. Participants
reported significantly lower levels of depression on the BDI
(18.18 vs. 13.64, p = 0.04) as well as a trend for lower level of
sleep disturbance (reflecting improved sleep) on the PSQI (9.63
vs. 7.25, p = 0.06). In addition, participants reported a moderate
degree of decreased impulsivity on the BIS (Motor subscore:
22.91 vs. 21.46, p = 0.03). On the SF-36, participants also
generally reported improved quality of life, including significant
improvements on a scale measuring Energy/Fatigue (35.45 vs.
45.91, p = 0.02) as well a trend for fewer role limitations due
to physical health (43.18 vs. 56.82, p = 0.07), which reflects how
often patients “cut down the amount of time [they] spent on work
or other activities,” “accomplished less than [they] would like,”
“were limited in the kind of work or other activities,” or “had
difficulty performing the work or other activities” as a result of
physical health.
Following 3 months of MMJ treatment, participants also
reported reductions in the use of conventional pharmaceutical
products. As shown in Table 4, percentage change [(Visit 2-
Visit 1)/Visit 1] data revealed a notable decrease in weekly use
across all medication classes, including reductions in use of
opiates (−42.88%), antidepressants (−17.64%), mood stabilizers
(−33.33%), and benzodiazepines (−38.89%). Interestingly,
t-tests indicated trends for significant reductions in opiate (5.85
vs. 2.27, p= 0.08) and antidepressant (8.54 vs. 7.00, p= 0.09) use.
Although sedative (−100.00%) and muscle relaxant (−100.00%)
usage were notably decreased, these data were only based on one
participant for each of these medication classes.
DISCUSSION
Despite rapid changes in the law, many policy makers,
consumers, physicians, and the general public remain
misinformed about MJ. While a body of evidence has
demonstrated alterations in brain structure and function
secondary to recreational MJ use, particularly related to use
during vulnerable developmental periods such as adolescence
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TABLE 2 | Cognitive performance at baseline (Visit 1) and after 3 months
(Visit 2) of MMJ treatment.
Neurocognitive
measure
Visit 1 Mean (SD) Visit 2 Mean (SD) 1-tailed t-test t (p)
TRAIL MAKING TEST
Trails A time (sec) 26.91 (6.63) 22.91 (3.89) 2.29 (0.02)
Trails A errors 0.36 (0.51) 0.55 (0.82) 0.69 (0.25)
Trails B time (sec) 64.18 (13.42) 54.00 (11.87) 1.72 (0.06)
Trails B errors 0.18 (0.41) 0.18 (0.41) 0.00 (0.50)
STROOP COLOR WORD TEST
Color naming
percent accuracy
97.46 (1.81) 97.81 (1.83) 1.31 (0.11)
Color naming time
(sec)
59.55 (15.85) 56.91 (14.19) 2.84 (0.01)
Word reading
percent accuracy
99.55 (1.04) 99.27 (1.27) 0.67 (0.26)
Word reading time
(sec)
44.09 (12.79) 43.46 (14.90) 0.69 (0.25)
Interference
percent accuracy
97.91 (1.81) 97.18 (3.06) 1.35 (0.10)
Interference time
(sec)
106.00 (27.15) 96.27 (20.66) 2.77 (0.01)
WISCONSIN CARD SORTING TEST
Total categories
completed
3.00 (1.10) 2.81 (1.16) 0.56 (0.29)
Total correct
responses
45.00 (8.10) 46.36 (8.24) 0.51 (0.31)
Total concept level
responses
39.18 (10.41) 41.91 (11.45) 0.84 (0.21)
Total perseverative
errors
8.36 (4.65) 7.82 (5.12) 0.35 (0.37)
LETTER-NUMBER SEQUENCING
Total correct 11.55 (2.54) 12.00 (2.83) 1.17 (0.14)
Values in bold represent statistically significant differences from Baseline to Visit 2 (p ≤
0.05), and italicized values represent statistical trends (p ≤ 0.10).
(For review: Crean et al., 2011; Jacobus and Tapert, 2014;
Lisdahl et al., 2014), critical questions regarding the impact of
MMJ use remain unanswered. To our knowledge, the current
pilot study marks the first investigation to specifically examine
cognitive performance and related measures in MMJ patients
prior to initiation of treatment relative to performance following
regular MMJ use. Preliminary results from this first phase
of the study suggest that after 3 months of MMJ treatment,
participants experienced some degree of improvement on tasks
of executive functioning. In addition, no significant decrements
in performance were noted across any measure of executive
function completed by participants.
Further, results from the current study suggested some
improvement in self-reported measures of clinical state
and general health. MMJ participants reported significant
improvement on measures of depression and impulsivity.
Participants’ ratings also indicated some improvement in
sleep quality, which is likely related to ratings of significantly
increased energy and decreased fatigue on self-report measures
assessing quality of life. Study findings provide further evidence
of improvements in medical and clinical symptoms secondary
TABLE 3 | Mood and health ratings at baseline (Visit 1) and after 3 months
(Visit 2) of MMJ treatment.
Rating scale Visit 1 Mean (SD) Visit 2 Mean (SD) 1-tailed t-test t (p)
CLINICAL RATING SCALES
Profile of Mood States (POMS)
Vigor 15.64 (6.85) 15.46 (6.67) 0.11 (0.46)
Anger 10.00 (12.16) 9.73 (9.73) 0.09 (0.46)
Confusion 9.18 (6.90) 8.10 (4.70) 0.87 (0.20)
Tension 15.55 (11.24) 15.10 (10.55) 0.17 (0.44)
Fatigue 11.27 (8.49) 11.18 (9.08) 0.08 (0.47)
Depression 16.18 (19.04) 19.18 (18.48) 0.76 (0.23)
TMD 46.55 (57.18) 47.82 (52.73) 0.12 (0.46)
Beck Depression Inventory (BDI)
Total 18.18 (13.00) 13.64 (13.75) 1.97 (0.04)
Beck Anxiety Inventory (BAI)
Total 13.46 (12.74) 13.36 (12.18) 0.03 (0.49)
IMPULSIVITY
Barratt Impulsiveness Scale (BIS-11)
Attention 18.73 (4.56) 18.82 (4.36) 0.10 (0.46)
Motor 22.91 (3.86) 21.46 (4.41) 2.10 (0.03)
Non-planning 23.82 (6.57) 24.45 (5.66) 0.53 (0.30)
Total 65.46 (14.07) 64.73 (12.67) 0.30 (0.39)
HEALTH AND QUALITY OF LIFE RATINGS
Pittsburgh Sleep Quality Index (PSQI)
Total 9.63 (4.84) 7.25 (3.69) 1.80 (0.06)
Short-Form 36 Healthy Survey (SF-36)
Physical
functioning
68.18 (26.20) 65.91 (30.23) 0.23 (0.41)
Role limitations
(physical)
43.18 (43.43) 56.82 (43.43) 1.40 (0.10)
Role limitations
(emotional)
57.58 (44.95) 54.55 (47.78) 0.22 (0.42)
Energy/fatigue 35.45 (25.34) 45.91 (24.47) 2.50 (0.02)
Emotional well
being
61.46 (27.56) 58.55 (27.20) 0.84 (0.21)
Social functioning 54.55 (29.72) 63.64 (31.35) 1.06 (0.16)
Pain 47.05 (34.15) 51.82 (30.95) 0.95 (0.18)
General health 54.55 (21.96) 55.46 (20.55) 0.20 (0.42)
Clinical rating scales (POMS, BDI, BAI), lower scores reflect lower levels of clinical
symptoms.
BIS-11, lower scores indicate lower levels of self-reported impulsivity.
PSQI, lower scores reflect improved sleep quality.
SF-36, higher scores indicate higher quality of life.
Values in bold represent statistically significant differences from Baseline to Visit 2 (p ≤
0.05), and italicized values represent statistical trends (p ≤ 0.10).
to MMJ use, consistent with other recent reports that have
also demonstrated varying degrees of efficacy of cannabinoid-
based therapies (Boychuk et al., 2015; Deshpande et al., 2015;
Press et al., 2015; Whiting et al., 2015; Devinsky et al., 2016;
Haroutounian et al., 2016; Wilkie et al., 2016).
In a survey study of California residents, Ryan-Ibarra et al.
(2015) recently found that of the 5% of California who reported
having ever used MMJ, 92% report that MMJ helped treat a
serious medical condition, with pain being the most commonly
reported indication for use. Notably, improvements observed
in the current study occurred concomitantly with a reduction
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TABLE 4 | Weekly medication usage (doses/week) between baseline (Visit 1) and after 3 months (Visit 2) of MMJ treatment.
Medication class Number of patients using medication Visit 1 Mean (SD) Visit 2 Mean (SD) 1-tailed t-test t (p) Percent change Mean (SD)
Opiates 6 5.85 (5.95) 2.27 (3.72) 1.66 (0.08) −42.88% (51.90)
Antidepressants 7 8.54 (3.95) 7.00 (4.04) 1.49 (0.09) −17.64% (37.05)
Mood Stabilizers 3 5.83 (2.02) 4.67 (4.04) 1.00 (0.21) −33.33% (57.73)
Benzodiazepines 6 5.90 (10.44) 0.50 (1.19) 1.12 (0.16) −38.89% (71.23)
Sedatives 1 5.00 (NA) 0.00 (NA) – −100.00% (NA)
Muscle Relaxants 1 3.50 (NA) 0.00 (NA) – −100.00% (NA)
in reported use of pharmaceutical products (particularly opiates
and antidepressants), which are used to treat many symptoms
for which patients in this study initiated MMJ use. In a
recent European study designed to assess the impact of MMJ
on chronic pain, Haroutounian et al. (2016) also reported
reductions in conventional pharmaceutical use among study
patients, specifically with regard to opioid use. Similarly, a study
examining physician records of 1655 patients seeking a physician
certification at multiple MMJ evaluation clinics in California
found that half of applicants reported using MJ as a substitute
for a prescription medication (Nunberg et al., 2013). Given the
current opioid crisis, it is critical to examine the potential role
for cannabinoids, as many patients do not get full symptom relief
from conventional opiate-based therapies and often complain
about the myriad of associated side effects (Ballantyne and Shin,
2008; Rosenblum et al., 2008). In addition, it is important to
consider a recent study which found that MJ users reported
greater pain relief when MJ was used in combination with
pharmaceutical opioids than when opioids were used alone
(Degenhardt et al., 2015).
Several hypotheses may be considered for the observed
improvements in the current pilot investigation. First, as
postulated, participants experienced some amelioration of
clinical symptoms. This reduction of symptomatology, in
combination with reported improvements on other measures
(improved sleep, less impulsivity), may result in the observed
improvements in cognitive functioning. As previously noted,
symptoms commonly reported in MMJ patients including
anxiety and pain, have been associated with reduced cognitive
performance (Moriarty et al., 2011; Vytal et al., 2013). Symptom
improvement may therefore result in improved cognitive
performance. Interestingly, two previous studies have noted a
positive association between a history of MJ use and improved
cognitive performance on measures of psychomotor speed,
attention, working memory, executive functioning, and verbal
learning in patients with bipolar disorder compared to patients
without a history of marijuana use (Ringen et al., 2010; Braga
et al., 2012). Further investigation is warranted, given the number
of patients seeking MMJ treatment for symptoms known to
interfere with cognitive function.
It is also possible that MMJ products themselves protect
against the executive function deficits that have been widely
reported in recreational MJ users (for review see Crean et al.,
2011). Although results from the current study appear to be in
stark contrast to those from some recreational MJ studies, the
answer may lie in the inherent differences between MMJ and
recreational MJ products and the differences between the two
consumer groups. While THC potency is rising and CBD levels
have decreased to barely perceptible levels in recreational MJ
strains (ElSohly et al., 2016), some MMJ products contain higher
amounts of CBD and other cannabinoids which may mitigate
the adverse effects of THC on cognitive performance. Although
research is limited in this area, Englund et al. (2013) found
that administering CBD prior to intravenous administration
of THC in healthy control participants resulted in better
episodic memory relative to placebo. In another study of acute
administration of CBD in recreational MJ users who smoked
once a month for at least a year, Morgan et al. (2010) reported
that those who smoked MJ strains low in CBD performed
worse on a verbal memory task than those who smoked MJ
strains high in CBD. Similarly, an extension of that study
examined THC and CBD levels obtained via hair samples and
found that higher levels of CBD were associated with better
recognitionmemory relative to undetectable CBD levels (Morgan
et al., 2012). While the majority of studies have investigated
the impact of CBD on verbal memory, Borgwardt et al. (2008)
utilized a Go/No Go Task, which measures inhibitory function,
to examine the functional impact of CBD in healthy volunteers.
Functional imaging results revealed that while THC reduced
activation in the right inferior frontal and anterior cingulate
gyrus, CBD deactivated the left temporal cortex and insula
relative to placebo. The authors concluded that THC may
attenuate the activity of brain regions that mediate response
inhibition, while CBD altered function in regions not typically
implicated in response inhibition. Bhattacharyya et al. (2010)
also found that intravenous administration of THC and CBD
had opposite effects on brain activation patterns across a
number of brain regions during the completion of memory,
inhibitory, visual, and affective measures. Taken together, these
results further suggest that THC and CBD appear to affect
the brain very differently, with CBD demonstrating potential
for mitigating adverse cognitive consequences that have been
widely observed in recreational MJ smokers. The current study
included individuals using products high in CBD as well as
those using products high in THC; future analyses which include
quantified levels of THC, CBD and several other cannabinoids
from participants’ actual MMJ products are planned in order to
examine the specific relationship between MJ constituents and
cognitive performance and to determine if some cannabinoids
prove beneficial to cognitive status.
In addition, it may be that some of the adverse consequences
noted in recreational MJ users were not noted in the current
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study as all enrolled patients are considered beyond the age
of neurodevelopmental vulnerability. Longitudinal studies have
shown that the brain continues to develop throughout the late
twenties (Giedd et al., 1999); however, all participants included
in the current analysis were over 30 years of age. Numerous
research studies have found that recreational MJ users with
teenage onset experience the most pronounced cognitive deficits
(Lisdahl et al., 2013,2014; Jacobus and Tapert, 2014), and those
with later onset of use often perform more similarly to non-
MJ smoking healthy control subjects (Gruber et al., 2012a;
Sagar et al., 2015). Accordingly, our adult MJ onset sample may
not be as vulnerable to the negative impact of MJ, specifically
products high in THC, as those who use MJ during periods of
developmental vulnerability.
Limitations and Future Directions
Although data from the current investigation have generated
interesting preliminary findings, it is important to consider
these results in light of several limitations. As a pilot study,
we have thus far only investigated the impact of MMJ use
on measures of executive functioning. Future studies should
explore additional cognitive domains. In addition, the sample
size is inherently modest in nature. However, additional subjects
continue to be recruited and enrolled. With additional subjects
and increased statistical power, future analyses can employ
regression models in order to determine whether MMJ use
patterns, product type, constituent ratios, indications for use, or
other additional factors predict cognitive performance, mood,
or symptom improvement. For example, while a number of
patients smoke or vaporize MJ flower products, several also
consistently used tinctures, oil, or edibles. In order to inform
policy and guidelines for use, research is needed to determine
whether certain modes of use have a differential impact on
cognition, quality of life, and clinical and medical symptoms.
Similarly, information gathered from laboratory analyses, which
provide information about the cannabinoid profiles of each
product, may provide critical data regarding the impact of
individual constituents and eventually, the impact of specific
ratios (i.e., THC: CBD) on cognitive and clinical measures. In
the current observational study, patients are free to use products
of their choice, and often “test out” a variety of products in
order to determine what works best for them, especially in
the early stages of treatment, which likely increases ecological
validity. In addition, with only a handful of dispensaries available
to those within the Greater Boston Area, patients in the
current study have reported being limited to what products
are currently available, and are sometimes forced to change
products due to changes in availability. Without statewide or
federal regulations to maintain quality control, products may
also vary in potency and composition over time or across
dispensaries. With larger sample sizes, we aim to explore
these questions more fully. For example, we plan to conduct
analyses which examine the possibility that high CBD-containing
products may have contributed to the positive changes in clinical
outcomes and perhaps mitigated some of the adverse cognitive
consequences that have historically been observed in recreational
MJ users.
Further, while this study employed a pre-post treatment
design to assess within-subject changes, given its observational
nature, a group of individuals taking placebo or receiving a
“sham” treatment could not be utilized; participants in this
investigation acquire MMJ products at their own discretion from
local dispensaries and/or caregivers, and therefore a placebo arm
is not possible. In subsequent work, we plan to utilize clinical
trials with more robust double-blind procedures; however, thus
far the Schedule I classification of MJ has impeded efforts to
conduct these types of clinical trials.
As the current study design requires participants to complete
repeated administrations of neurocognitive assessment, we
cannot exclude the possibility of practice effects impacting study
findings despite attempts to minimize this potential confound.
While tasks completed at the baseline visit would be familiar
to subjects at Visit 2, it is unlikely that practice effects would
persist following a 3-month interval between study visits. For
example, a study of practice effects in serial neuropsychological
testing found no effects on the Letter Number Sequencing and
Trail Making tasks even with weekly administration (Beglinger
et al., 2005)—a much more frequent schedule of testing than
utilized in the current study. Studies noting practice effects
on the Stroop test have typically utilized a daily to weekly
administration, also a significantly more frequent interval than
3 months (Gul and Humphreys, 2015). In addition, we utilized
alternate versions of test measures at Visit 2, further reducing the
risk of practice effects. For complex tasks like the WCST, where
no alternate version exists, a computerized version of the task,
which terminates upon the completion of a specific number of
correct categories without any clarification of the rules, was used
in order to reduce potential task learning.
In the past, we have had success in studies of recreational users
using TLFB procedures to track MJ use (Gruber et al., 2012a,b,
2014; Sagar et al., 2015, 2016; Dahlgren et al., 2016). While MMJ
patients appear to be truthful and accurate in providing data on
frequency andmagnitude of use, the accuracy of their self-reports
cannot be confirmed. However, to address this challenge, reports
of use during phone check-ins were verified and reviewed at
patients’ second in-person visit. In general, quantification of MJ
use continues to be a challenge in all research studies, as unlike
other substances, no standard measure of use is available. This is
especially true when considering concentrated products, which
often contain high levels of THC (i.e., greater than 60%) in a
very small volume or weight. AlthoughMMJ use information was
collected and primary MMJ use variables are reported (i.e., days
used per week, times used per day), future studies will explore
the impact of MMJ use patterns (frequency, mode, constituent
ratios, age of initiation, duration of use, mode of use, etc.) and
MMJ product composition (i.e., THC vs. CBD), analyses which
are planned once larger sample sizes are achieved. Clinical trials
geared specifically toward assessing individual MMJ products are
still needed to help address issues of confounding variables and to
provide additional data regarding the myriad of questions, which
only continue to grow as we learn more about MMJ.
Additionally, it will also be important to ascertain whether
the improvements noted in the current study persist over
longer periods of time. For this reason, the current study is
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designed to continue to track subjects’ cognitive performance
and clinical state over the course of 1 year of treatment.
Future studies should also investigate whether specific clinical
indications forMMJ use impact study results.While some studies
have already begun to investigate the effects of cannabinoid-
based treatments for specific illnesses or symptoms, such as
pain (Eisenberg et al., 2014; Baron, 2015), multiple sclerosis
(Flachenecker et al., 2014; Patti et al., 2016), and epilepsy
(Press et al., 2015; Devinsky et al., 2016), it is critical to
assess whether use of MMJ and related products differentially
impact cognition within these populations. Finally, future
investigations should aim to explore the mechanism of the
improvement noted in the current study. For example, as results
primarily indicate improvements in task completion times, more
focused examinations of the effects of processing speed may be
warranted.
Although our research has begun to address the potential
impact of MMJ treatment on cognition, more questions than
answers remain. Our findings underscore the need for additional,
expanded investigation and exploration. With the nation in the
midst of a “green rush” (Silver, 2016) it is imperative to clarify
issues including the ways in which recreational and medical MJ
use differ. Further, given previous studies assessing the impact
of recreational MJ use in adolescents or emerging adults (Crean
et al., 2011; Gruber et al., 2012a,b, 2014; Jacobus and Tapert,
2014; Lisdahl et al., 2014; Sagar et al., 2015, 2016; Dahlgren et al.,
2016), it will be critical to determine if the same decrements
are noted in adult consumers who use MMJ for short or long-
term symptom alleviation. Questions regarding how MMJ use
impacts quality of life, sleep, clinical state and other important
measures remain and are critical areas for further longitudinal
investigations.
Given the fact that more than 22 million Americans report
current use of recreational MJ (Center for Behavioral Health
Statistics and Quality, 2015) and more than 1 million are
certified for MMJ use (Procon.org4), it is in the public’s best
interest to develop a robust, evidence-based understanding of
both the positive and negative effects of MMJ use on various
aspects of functioning: cognition, quality of life, physical and
emotional health. Despite attempts to conduct empirically sound
clinical research, a number of barriers remain. Restrictions on
MJ research and many MJ-related products, including those
with little to no THC, stem exclusively from MJ’s status as a
Schedule I substance. Budding efforts have emerged to move the
field forward, including both the introduction of the CARERS
Act (Compassionate, Access, Research Expansion, and Respect
States Act, 20155) and the Therapeutic HempMedical Access Act
(Therapeutic HempMedical Access Act, 2015). Both of these acts
seek, among other agenda items, to exclude CBD as well as low
THC/high CBD strains of MJ (in other words, non-psychoactive
products) from the current definition of “marijuana” under the
CSA in order to facilitate access to MMJ patients. Although both
bills were introduced over a year ago, their status is still pending.
4Medical Marijuana ProCon.org. (2016). Retrieved June 16, 2016, from http://
medicalmarijuana.procon.org/
5Compassionate Access, Research Expansion, and Respect States Act of 2015, S.
683, 114th Cong. (2015).
As it currently stands, non-psychoactive (low to no THC)
industrial hemp-derived products, which are widely available
for sale, cannot be studied through clinical research trials given
current restrictions. Accordingly, consumers can gain access to
these products that cannot be assessed by clinical researchers with
regard to efficacy and safety. In spite of these obstacles, some
progress has recently provided hope to those who seek alternative
treatments. As of April 2016, the DEA approved the first study of
smokedMMJ for a clinical trial of Post-Traumatic Stress disorder
(Clinicaltrials.gov6). Although the DEA announced earlier this
year that it was reconsidering the classification of MJ, a decision
released in August 2016 revealed that MJ will remain a Schedule I
substance (Department of Justice, 2016a). In an effort to promote
clinical research studies of MJ, the DEA instead indicated that it
will allow “entities” to apply for a DEA registration to grow their
own MJ for research (Department of Justice, 2016b); this stands
in contrast to the current protocol mandating that all whole
plant-derived MJ products used for clinical trials be sourced
from the National Institutes of Drug Abuse (NIDA). While
investigations of the purified extracts of individual cannabinoids
are currently being studied, most notably the GW Pharma trials
of Epidiolex, a purified CBD product for children with intractable
seizure disorders, some have reported that products derived from
whole plant botanicals provide greater symptom amelioration
and relief (Grinspoon and Bakalar, 1997; Joy et al., 1999),
underscoring the need for additional sources of MJ products for
clinical trials.
CONCLUSIONS
Data from the current investigation provide preliminary
evidence that after 3 months of treatment, MMJ users did
not experience executive functioning deficits, which are often
observed in regular, recreational MJ users. In fact, MMJ patients
evidenced improvement in certain aspects of performance on
these measures, particularly with regard to time required to
complete tasks. Further, patients reported some improvements
on measures of clinical state and general health as well as a
decrease in conventional pharmaceuticals, notably opiate use,
which was reduced by 42% between the baseline and Visit 2
assessment. While future studies are needed to further examine
the impact of MMJ, research is impeded by a number of
federal and state restrictions. It is imperative, however, that
sound research, including well-controlled clinical trials of MMJ
products, many of which are already widely used by patients,
are thoroughly examined. As the “green rush” pushes forward,
gaining momentum as states continue to adopt less restrictive
policies, we cannot afford for research to continue to lag behind.
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